Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 11 March (HL15135), in what circumstances a direction under the statutory instrument coming into force on 24 March would not be made.

It is important that there is stability in the medicines regulatory and access landscape, and there should be a high bar for making changes to the cost-effectiveness threshold. It is the Government’s intention, therefore, that the power to set the cost-effectiveness threshold would be used rarely.